Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Human Metabolome TechnologiesTSE:6090 -0.32%62 Return-on-Tangible-Equity is 26.70% as of Mar. 2026, which is 4755% above its 10-year median of 0.55. GuruFocus rates TSE:6090 with a GF Score™ of 62/100 and a GF Value™ of 円694.71 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 188 Medical Diagnostics & Research companies, Human Metabolome Technologies ranks better than 67.02% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Human Metabolome Technologies's annualized net income for the quarter that ended in Mar. 2026 was 円487 Mil. Human Metabolome Technologies's average shareholder tangible equity for the quarter that ended in Mar. 2026 was 円1,826 Mil. Therefore, Human Metabolome Technologies's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 26.70%.
The historical rank and industry rank for Human Metabolome Technologies's Return-on-Tangible-Equity or its related term are showing as below:
TSE:6090'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -22.72 Med: 0.55 Max: 19.58
Current: 11.11
During the past 13 years, Human Metabolome Technologies's highest Return-on-Tangible-Equity was 19.58%. The lowest was -22.72%. And the median was 0.55%.
TSE:6090's Return-on-Tangible-Equity is ranked better than 67.02% of 188
companies
in the Medical Diagnostics & Research industry
Industry Median: 1.05
vs TSE:6090: 11.11
Human Metabolome Technologies (TSE:6090) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Human Metabolome Technologies Return-on-Tangible-Equity Related Terms
Human Metabolome Technologies Return-on-Tangible-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Human Metabolome Technologies Return-on-Tangible-Equity Chart
TSE:6090 vs TMO, DHR, NTRA: Return-on-Tangible-Equity Comparison
For the Diagnostics & Research subindustry, Human Metabolome Technologies's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Human Metabolome Technologies Return-on-Tangible-Equity vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Human Metabolome Technologies's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Human Metabolome Technologies's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 26.70% mean?
Human Metabolome Technologies (TSE:6090) has a Return-on-Tangible-Equity of 26.70% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Human Metabolome Technologies and its competitors. This is 4755% above median its historical median of 0.55. According to the industry distribution chart, Human Metabolome Technologies ranks #62 out of 188 companies in the Medical Diagnostics & Research industry, placing it in the top 33%.
Is Human Metabolome Technologies' Return-on-Tangible-Equity too high?
Human Metabolome Technologies' current Return-on-Tangible-Equity of 26.70% is 4755% above median its 10-year median of 0.55. The Medical Diagnostics & Research industry median Return-on-Tangible-Equity is 1.05. Human Metabolome Technologies' value of 26.70% is 2442.9% above this industry median. Based on the distribution chart, Human Metabolome Technologies ranks #62 out of 188 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Human Metabolome Technologies has a GF Score™ of 62/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Human Metabolome Technologies' Return-on-Tangible-Equity compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Human Metabolome Technologies ranks #62 out of 188 companies for Return-on-Tangible-Equity. This puts Human Metabolome Technologies in the upper half of its industry. The industry median Return-on-Tangible-Equity is 1.05. Human Metabolome Technologies' value of 26.70% is 2442.9% above this benchmark. While the company's 10-year median is 0.55 vs. the industry median of 1.05, Human Metabolome Technologies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Diagnostics & Research company?
The median Return-on-Tangible-Equity among Medical Diagnostics & Research companies is 1.05, based on 188 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Human Metabolome Technologies's current Return-on-Tangible-Equity of 26.70% is 2442.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Human Metabolome Technologies and its competitors. For the Medical Diagnostics & Research industry, the median Return-on-Tangible-Equity is 1.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Human Metabolome Technologies's current Return-on-Tangible-Equity is 26.70%, which is 4755% above median its own 10-year median of 0.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Human Metabolome Technologies stock overvalued right now?
Based on GuruFocus' analysis, Human Metabolome Technologies (TSE:6090) is currently considered Modestly Undervalued. The stock's GF Value™ is 円694.71, compared to a current price of 円614.00 — trading 11.6% below its estimated fair value. The current Return-on-Tangible-Equity is 26.70%, which is 4755% above median its 10-year median of 0.55 and 2442.9% above the Medical Diagnostics & Research industry median of 1.05. Human Metabolome Technologies' overall GF Score™ is 62/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Human Metabolome Technologies (TSE:6090), the current Return-on-Tangible-Equity is 26.70% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Human Metabolome Technologies (TSE:6090) Overvalued in 2026?
Based on GuruFocus' analysis, Human Metabolome Technologies stock appears to be undervalued.
The current stock price of 円614.00 is trading 11.6% below its estimated GF Value™ of 円694.71.
GuruFocus considers Human Metabolome Technologies to be Modestly Undervalued.
Key valuation signals for TSE:6090:
Return-on-Tangible-Equity: 26.70% (4755% above median its 10-year median of 0.55)
GF Value™: 円694.71 vs. price of 円614.00 (11.6% below fair value)
Industry Position: 2442.9% above the Medical Diagnostics & Research median (#62 of 188)
No single metric tells the full story. See the TSE:6090 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:6090 has been successfully added to your 
